XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...
Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease progression or death in HRR gene-mutated metastatic ...
Hosted on MSN
Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication
Pfizer (PFE) announced on Thursday that its cancer drug regimen, Talzenna plus Xtandi, met the primary endpoint in a Phase 3 trial for a new indication in prostate cancer. Xtandi, marketed by Pfizer ...
A global phase 3 trial enrolled mHSPC with ≥90% PTEN loss by IHC and randomized 1,012 patients to intermittent capivasertib plus abiraterone/prednisone versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results